SHILPAMED.NSSHILPAMED.NSNSE
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank50
3Y CAGR+7.3%
5Y CAGR-1.7%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+7.3%/yr
vs -5.5%/yr prior
5Y CAGR
-1.7%/yr
Recent acceleration
Acceleration
+12.8pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
202524.16%+13.3%
202421.33%+96.1%
202310.87%-44.4%
202219.56%-35.4%
202130.29%+15.0%
202026.34%+2.1%
201925.80%+5.4%
201824.48%-4.4%
201725.60%-2.7%
201626.30%-